Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid.

Introduction: Neuronal-derived exosomal A beta 42, T-tau, and P-T181-tau have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, no study has assessed the association of A beta 42, T-tau, and P-T181-tau between exosomes and CSF. Methods: This was a multicenter study with two-stage design. The subjects included 28 AD patients, 25 aMCI patients, and 29 controls in the discovery stage; the results of which were confirmed in the validation stage (73 AD, 71 aMCI, and 72 controls). Results: The exosomal concentrations of A beta 42, T-tau, and P-T181-tau in AD group were higher than those in aMCI and control groups (all P < .001). The level of each exosomal biomarker was highly correlated with that in CSF. Discussion: This study verified the agreement between CSF and blood exosomal biomarkers and confirmed that exosomal A beta 42, T-tau, and P-T181-tau have the same capacity as those in CSF for the diagnosis of AD and aMCI. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.